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Major depression is the most common form of mental illness, and is treated with antidepressant 
compounds that increase serotonin (5-HT) neurotransmission. Increased 5-HT1A autoreceptor 
levels in the raphe nuclei act as a “brake” to inhibit the 5-HT system, leading to depression and 
resistance to antidepressants. Several 5-HT1A receptor agonists (buspirone, flesinoxan, ipsapirone) 
that preferentially desensitize 5-HT1A autoreceptors have been tested for augmentation of 
antidepressant drugs with mixed results. One explanation could be the presence of the C(−1019)
G 5-HT1A promoter polymorphism that prevents gene repression of the 5-HT1A autoreceptor. 
Furthermore, down-regulation of 5-HT1A autoreceptor expression, not simply desensitization 
of receptor signaling, appears to be required to enhance and accelerate antidepressant action. 
The current review focuses on the transcriptional regulators of 5-HT1A autoreceptor expression, 
their roles in permitting response to 5-HT1A-targeted treatments and their potential as targets 
for new antidepressant compounds for treatment-resistant depression.
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somatodendritic autoreceptor on 5-HT neurons (Sotelo et al., 1990; 
Riad et al., 2000) where it acts as a “brake” to inhibit the activity of the 
entire 5-HT system (Hjorth et al., 1996; Richer et al., 2002; Bortolozzi 
et al., 2004) (Figure 1). Hence, the mechanisms that regulate 5-HT1A 
autoreceptor levels set the tone of the 5-HT system.
5-HT1A recepTors in depression
5-HT1A recepTors in AnimAl models of depression
Despite their limited validity to model human depression, animal 
behavioral studies have provided valuable insights into the bio-
logical function of 5-HT1A receptors in depression and anxiety. 
Importantly, 5-HT1A-null mice display increased anxiety behavior 
(Heisler et al., 1998; Parks et al., 1998; Ramboz et al., 1998) and are 
unresponsive to SSRI treatment (Santarelli et al., 2003), while early 
developmental overexpression of the 5-HT1A receptor decreases 
anxiety (Kusserow et al., 2004). 5-HT1A receptor expression in 
early postnatal forebrain of 5-HT1A−/− mice rescues the anxiety 
phenotype, suggesting that post-synaptic 5-HT1A receptors are 
critical in the development of the anxiety phenotype (Gross et al., 
2002). Conversely, mice with a 30% increase in 5-HT1A autorecep-
tors display reduced 5-HT neuron firing, reduced 5-HT release, 
increased depression behavior, but no change in anxiety behavior 
(Richardson-Jones et al., 2010). Hence, while reduction in post-
synaptic 5-HT1A receptors is implicated in anxiety, increased levels 
of presynaptic 5-HT1A autoreceptors inhibit 5-HT neurotransmis-
sion and leads to depression (Figure 1).
5-HT1A recepTors in clinicAl depression
In human depression, there remain conflicting findings concerning 
changes in 5-HT1A binding potential (Savitz et al., 2009). Most stud-
ies find reductions in post-synaptic 5-HT1A receptors in subsets 
of prefrontal and temporal cortical regions in depression (Sargent 
et al., 2000; Bhagwagar et al., 2004; Shively et al., 2006; Moses-Kolko 
inTroducTion
depression And seroTonin
Major depression is the most prevalent form of mental illness, twice 
as frequent in women as in men (Doris et al., 1999; Fava and Kendler, 
2000), and is predicted to increase from fourth to second (first in high 
income countries) highest global burden of disease by 2030 (Ustun 
et al., 2004; Mathers and Loncar, 2006). There is a need for improved 
antidepressant treatments since only 30% of patients remit with cur-
rent strategies (Trivedi et al., 2006a,b, 2008), while 15% attempt suicide 
(Mann et al., 2001; Mann, 2005). Although other neurotransmitters 
(e.g., noradrenaline, dopamine, glutamate, neurotrophins) are indi-
rectly involved in depression (Blier, 2003; Duman, 2004; Nestler and 
Carlezon Jr., 2006; Skolnick et al., 2009), multiple lines of evidence 
implicate reduced 5-HT neurotransmission as a primary defect in 
depression (Millan, 2004; Wong et al., 2005; Tremblay and Blier, 2006; 
Jans et al., 2007; aan het Rot et al., 2009). Virtually all antidepressant 
treatments, including serotonin reuptake inhibitors (SSRIs), increase 
5-HT neurotransmission, either directly or indirectly (Blier, 2003; 
Berton and Nestler, 2006; Savitz et al., 2009).
5-HT1A recepTors And THe 5-HT sysTem
The brain serotonin (5-HT) system originates from neurons of the 
raphe nuclei that express tryptophan hydroxylase 2 (TPH2), the rate-
limiting enzyme for 5-HT synthesis (Walther et al., 2003). These neu-
rons project widely throughout the brain (Hornung, 2003) to regulate 
many physiological functions, including sleep, mood and stress reac-
tivity and are implicated in mental illnesses, including MDD and anxi-
ety (Barnes and Sharp, 1999; Young and Leyton, 2002; Gordon and 
Hen, 2004; Lanfumey et al., 2008; Savitz et al., 2009). Among the 17 
human 5-HT receptor genes, we have focused on the 5-HT1A receptor 
since it is abundant in corticolimbic regions that are implicated in 
mood and emotion (Albert et al., 1996; Albert and Lemonde, 2004). 
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reverses changes in 5-HT1A receptor RNA expression in chronic 
stress models (Burnet et al., 1995; Greenwood et al., 2003, 2005; 
Morley-Fletcher et al., 2004), as well as in depression (Lopez et al., 
1998; Lopez-Figueroa et al., 2004). However, several studies in “nor-
mal” animals have found that chronic antidepressant treatments 
desensitize 5-HT1A receptors without a concomitant reduction 
in receptor levels (Le Poul et al., 1995; Elena Castro et al., 2003; 
Rossi et al., 2008). Because acute desensitization (uncoupling and 
internalization) occurs rapidly (second–minute) and is reversible 
(Riad et al., 2001, 2004), we postulated that acute desensitization 
is not sufficient for antidepressant response, but that a reduction 
in the synthesis of new 5-HT1A receptors may be required, and 
could account for the longer time course of the treatment (Albert 
et al., 1996; Albert and Lemonde, 2004). Interestingly, a 30% reduc-
tion in 5-HT1A autoreceptors is sufficient to permit a rapid and 
robust response to chronic SSRI treatment in mice that do not 
otherwise respond (Richardson-Jones et al., 2010), suggesting that 
transcriptional down-regulation of the 5-HT1A mRNA could be a 
key mechanism in determining antidepressant response.
TrAnscripTionAl regulATion of THe 5-HT1A recepTor 
gene in menTAl illness
TrAnscripTionAl regulATion of THe 5-HT1A recepTor gene
Based on the hypothesis that impaired repression of the 5-HT1A 
receptor gene may predispose individuals to depression, we have 
identified key transcription regulators of the 5-HT1A receptor 
et al., 2008) and anxiety (Tauscher et al., 2001; Neumeister et al., 
2004; Sullivan et al., 2005; Lanzenberger et al., 2007; Nash et al., 
2008; Akimova et al., 2009). In contrast, 5-HT1A autoreceptors are 
increased in depressed patients (Parsey et al., 2006a,b) and in post-
mortem raphe tissue from depressed suicide victims (Stockmeier 
et al., 1998; Boldrini et al., 2008). However, decreases in raphe 
5-HT1A binding have also been reported, but may reflect a reduc-
tion in 5-HT neurons (Drevets et al., 2007). These region-specific 
alterations in 5-HT1A receptor levels in depression are consist-
ent with a global reduction in 5-HT neurotransmission, since 
increased 5-HT1A autoreceptors reduce 5-HT neuronal activity, 
while reduced post-synaptic 5-HT1A receptors reduce behavioral 
response to 5-HT (Albert and Lemonde, 2004).
5-HT1A recepTors in AnTidepressAnT response
Although SSRIs rapidly enter the brain and block 5-HT reuptake, 
chronic 3-week treatment is required for clinical response, due to 
recurrent inhibition of raphe activity by 5-HT1A autoreceptors 
(Figure 1). During this period, 5-HT1A autoreceptors desensitize 
(Le Poul et al., 1995; Mochizuki et al., 2002; Shen et al., 2002; Elena 
Castro et al., 2003), leading to reduced 5-HT1A RNA and autorecep-
tor levels, particularly in animal models of depression and depressed 
subjects (Welner et al., 1989; Fanelli and McMonagle-Strucko, 1992; 
Sibug et al., 1998; Le Poul et al., 2000; Meltzer et al., 2004; Rabiner 
et al., 2004; Berney et al., 2008), resulting in restoration of raphe 
firing activity and 5-HT release. Chronic antidepressant treatment 
Figure 1 | regulation of 5-HT1A receptors in depression. Shown figuratively 
are 5-HT1A-expressing presynaptic raphe neuron and post-synaptic prefrontal 
cortical neuron. The 5-HT1A gene and its regulators (Deaf1, Freud-1, Freud-2, 
REST, Hes) are shown; 5-HT1A receptors (circle/triangle) and serotonin (triangles) 
are shown to indicate expected changes in their levels in depression. In 
depression, 5-HT1A receptor RNA and protein levels are increased 
presynaptically, leading to inhibition of 5-HT neurons (red-) and reduced firing. 
Paradoxically, the presynaptic levels of repressors REST and Deaf1 are increased, 
and there is also a trend for increase in Freud-1, perhaps to compensate for 
5-HT1A overexpression due to the G(−1019) allele, for example. Post-synaptically, 
5-HT1A receptors appear reduced, and levels of Deaf1 are also lower, although 
Freud-1 and Freud-2 (trend) increase. See text for details and references.www.frontiersin.org    June 2010  | Volume 4  | Article 35  |  3
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Recently, the homozygous 5-HT1A G/G(−1019) risk genotype 
has been associated with increased levels of 5-HT1A autorecep-
tors in the raphe of depressed and bipolar depressed subjects 
(Parsey et al., 2006b; Sullivan et al., 2009), which is consistent 
with the increase in 5-HT1A autoreceptors observed in post-
mortem studies of depressed suicides (Stockmeier et al., 1998; 
Drevets et al., 2007; Boldrini et al., 2008). This association sup-
ports the hypothesis that the 5-HT1A G(−1019) allele is a risk 
factor for depression by increasing 5-HT1A autoreceptor levels 
to reduce 5-HT neurotransmission (Albert and Lemonde, 2004). 
Interestingly, in serotonin neurons of depressed females, RNA 
levels of both Deaf1 and REST [a repressor of 5-HT1A receptor 
transcription (Lemonde et al., 2004b)] are increased, suggesting 
a compensatory change to re-establish normal 5-HT1A autore-
ceptor levels (Goswami et al., 2010). Despite these compensatory 
changes, there was a trend toward increased 5-HT1A RNA levels 
in depressed female raphe tissue, consistent with previous studies 
showing increased 5-HT1A autoreceptors. The recent finding that 
mice with selective increase in presynaptic 5-HT1A autorecep-
tors have depression-like behavior and are resistant to antide-
pressants (Richardson-Jones et al., 2010), provides validation of 
the hypothesis that dysregulation of the 5-HT1A autoreceptor is 
implicated in major depression (Albert et al., 1996; Albert and 
Lemonde, 2004).
In  addition  to  its  association  with  depression,  we  and 
others have found that the G(−1019) allele associates with 
reduced response to chronic SSRI or SSRI/pindolol treatment 
(Lemonde et al., 2004a; Le François et al., 2008; Villafuerte 
et al., 2009; Yevtushenko et al., 2010). Interestingly, antidepres-
sant response to flibanserin, a 5-HT1A agonist which directly 
targets 5-HT1A receptor desensitization, was the most attenu-
ated in subjects with the G/G genotype. This suggests that the 
Deaf1 site is critical for antidepressant action to down-regulate 
5-HT1A  autoreceptor  expression.  However,  particularly  in 
Asian populations where the G-allele is more prevalent, there 
is evidence that SSRI response is greater in the G/G genotype 
(Kato et al., 2009), suggesting that alternate regulatory factors 
(e.g., Freud-1, REST) could augment 5-HT1A autoreceptor 
down-  regulation. Therefore, mechanisms preventing 5-HT1A 
autoreceptor de-  repression could provide effective therapy for 
treatment-resistant depressed patients.
Thus, alterations in transcription factors that regulate 5-HT1A 
expression could either contribute to the dysregulation of the recep-
tor or compensate for changes associated with mental illness.
TArgeTing 5-HT1A AuTorecepTors for AnTidepressAnT 
response
TArgeTing 5-HT1A AuTorecepTors To AugmenT To 
AnTidepressAnT efficAcy
Several compounds that target 5-HT1A receptors including pin-
dolol and buspirone, have been used in augmentation with SSRIs 
to accelerate or enhance their antidepressant action. Pindolol 
is a β-adrenergic receptor blocker also shown to act as a weak 
partial agonist of the 5-HT1A receptor (Newman-Tancredi et al., 
1998). Pindolol preferentially competes with endogenous 5-HT 
at presynaptic 5-HT1A receptors (Rabiner et al., 2004; Serrats 
et al., 2004) to increase serotonergic neurotransmission. Clinical 
(Albert et al., 1996; Albert and Lemonde, 2004). The 5-HT1A recep-
tor gene is intronless with a non-selective CG-rich housekeeping 
promoter containing multiple strong Sp1/MAZ enhancers that 
drive expression in all cells (Albert et al., 1996; Parks and Shenk, 
1996; Storring et al., 1999) and an upstream repressor region that 
silences its expression in non-neuronal cells, but also represses 
transcription in neuronal cells that express 5-HT1A receptors (Ou 
et al., 2000; Lemonde et al., 2004b). The promoter also contains 
an NFkB-response element, that may mediate 5-HT1A induc-
tion in immune cells, although its function in neurons remains 
unaddressed. Repressors include Freud-1/CC2D1A and Freud-2/
CC2D1B (Five-prime Repressor Element Under Dual repression 
binding protein), calcium-sensitive repressors of pre- (Freud-1) 
and post-synaptic 5-HT1A receptor expression in neurons (Ou 
et al., 2003; Lemonde et al., 2004b; Hadjighassem et al., 2009). 
We have also identified Deaf1 and Hes1/Hes5 as regulators at 
the  C(−1019)G  5-HT1A  polymorphism  that  repress  5-HT1A 
autoreceptor transcription at the C-allele but not the G-allele 
(Lemonde et al., 2003). Consistent with this, the G/G genotype 
is associated increased 5-HT1A autoreceptor binding potential 
in depressed subjects (Parsey et al., 2006b). Deaf1 is colocalized 
with 5-HT1A receptors in raphe and post-synaptic neurons, and 
expressed from development to adulthood; while Hes proteins are 
restricted to neural precursors and immature neurons. In Hes1−/− 
mice, 5-HT1A receptor RNA expression is greatly up-regulated 
in embryonic midbrain (Jacobsen et al., 2008), suggesting that 
the G(−1019) allele may result in an early embryonic alteration 
in 5-HT1A receptor levels. Interestingly, Deaf1 displays tissue-
specific activity, repressing 5-HT1A autoreceptor RNA and protein 
expression in raphe cells, but enhancing 5-HT1A promoter activity 
in non-serotonergic neurons (Lemonde et al., 2003; Czesak et al., 
2006). Based on this, the G-allele is expected to increase 5-HT1A 
autoreceptor levels to reduce 5-HT neuronal activity, and decrease 
post-synaptic 5-HT1A receptors, synergistically reducing 5-HT 
neurotransmission.
TrAnscripTionAl dysregulATion of THe 5-HT1A recepTor gene in 
menTAl illness
Changes in 5-HT1A receptor RNA and protein levels are observed 
in brain regions of MDD subjects as discussed above, and sug-
gest that alterations in 5-HT1A receptor gene expression could 
confer susceptibility. We initially associated the C(−1019)G poly-
morphism with MDD and suicide (Lemonde et al., 2003). This 
association has been replicated in most studies (Parsey et al., 
2006b; Anttila et al., 2007; Kraus et al., 2007; Le François et al., 
2008; Kishi et al., 2009; Neff et al., 2009). In our original study 
(Lemonde et al., 2003), both G/G genotype (P = 0.0134*) and 
G-allele frequencies (P = 0.0043**) were associated with depres-
sion in females (81 normal; 74 depressed). Males (53 control; 
55 depressed) showed the same trends for genotype and allele 
frequency (P = 0.0846 and 0.0574), but they were not significant, 
suggesting a stronger association in females. However the allele 
and genotype ratios in depressed/control were similar (G/G gen-
otype frequency 2.36× and 2.39× for females and males; G-allele 
frequency 1.45× and 1.33×). Hence there does not appear to 
be a clear gender effect of the polymorphism for association 
with depression.Frontiers in Neuroscience  |  NeuroPharmacology    June 2010  | Volume 4  | Article 35  |  4
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studies have demonstrated that pindolol can accelerate response 
to SSRIs, even in drug-resistant depression (Artigas et al., 1994; 
Blier and Bergeron, 1995; Portella et al., 2009). However, the 
ability of pindolol to improve SSRI treatment has not been con-
sistent, in part due to low occupancy of 5-HT1A receptor sites 
at the dose of pindolol used in most studies (Martinez et al., 
2000). In contrast to pindolol, buspirone functions as strong 
5-HT1A partial agonist that can specifically desensitize 5-HT1A 
autoreceptors (Sim-Selley et al., 2000) to relieve serotonergic 
autoinhibition.  Similarly  to  pindolol,  buspirone  was  able  to 
improve SSRI treatment in some studies (Harvey and Balon, 
1995; Trivedi et al., 2006a) but not consistently (Blier and Ward, 
2003). Differences between pindolol and buspirone appear due 
to their differential antagonist or agonist activity at 5-HT1A 
receptors. For example, unlike buspirone, acute pindolol treat-
ment potentiates citalopram-mediated increase in 5-HT in rats 
(Hjorth, 1996). However, buspirone has unique agonist activities 
that can differ from full agonists like 5-HT. Buspirone and its 
analog BMY7378 inhibited Gi2-dependent constitutive activity 
of the 5-HT1A receptor, while full agonists (5-HT, 8OH-DPAT) 
or antagonists WAY100635, pindolol and NAN-190 had little 
or no effect (Albert et al., 1999). In the raphe nuclei, buspirone 
recruits Gi2, Gi3, and Go to the 5-HT1A receptor and inhibits 
adenylyl cyclase, while 8OH-DPAT only recruited Gi3 and did 
not inhibit forskolin-stimulated adenylyl cyclase (Valdizan et al., 
2009). The preferential activity of buspirone in raphe cells may 
explain the efficacy of buspirone to decrease 5-HT synthesis in 
olfactory-bulbectomized rats (Watanabe et al., 2006). Other com-
pounds that act at 5-HT1A receptors, such as atypical antip-
sychotics aripiprazole (Abilify) or SNRI milnacipran (Savella), 
can also ameliorate response to SSRIs. However, while these 
compounds desensitize the 5-HT1A autoreceptor (Mochizuki 
et al., 2002), they have other targets that can participate in their 
antidepressant actions. In addition it is important to note that 
drugs that indirectly target 5-HT neurons (Guiard et al., 2008) 
such as bupropion or α2-adrenergic receptor antagonists may 
also enhance response to SSRI response (Tremblay and Blier, 
2006; Trivedi et al., 2006a; Blier et al., 2010). Thus, the concept of 
a multi-system therapeutic strategy appears to provide enhanced 
treatment response and remission rates compared to SSRI alone 
(Blier et al., 2010).
TArgeTing 5-HT1A gene TrAnscripTion for THe TreATmenT of 
depression
The inconsistent results using 5-HT1A agonists to augment or 
accelerate response to SSRIs, may be due to their limited ability 
to decrease presynaptic 5-HT1A receptor levels. In fact, effec-
tive treatment appears to require long-term adaptive changes in 
addition to rapid desensitization of 5-HT1A autoreceptors, such 
as reduced transcription of 5-HT1A autoreceptors or induction 
of post-synaptic 5-HT1A receptors. For example, it was recently 
shown  that  aripiprazole  increases  hippocampal  and  cortical 
5-HT1A receptors (Han et al., 2009). This suggests that long-term 
activation of presynaptic 5-HT1A receptors might trigger tran-
scriptional changes that follow the rapid initial desensitization of 
the receptors and lead to long-term alterations in 5-HT1A recep-
tor levels. The recent finding that a 30% transcription-mediated 
increase in 5-HT1A   autoreceptors is sufficient to abolish response 
to chronic   antidepressant treatment in adult mice (Richardson-
Jones et al., 2010), suggests that an ability to even slightly down-
regulate 5-HT1A autoreceptor expression could greatly improve 
SSRI response in treatment-resistant patients.
Additionally, it would be important to determine how 5-HT1A 
agonists affect the expression and activity of key transcriptional 
regulators of the 5-HT1A receptor gene. Recent findings sug-
gested that alterations in Deaf1 occur both in raphe and prefron-
tal cortex of depressed females (Szewczyk et al., 2009; Goswami 
et al., 2010), suggesting that females may be more responsive 
to drugs that could upregulate Deaf1 expression. Up-regulation 
of Deaf-1 levels would be expected to repress presynaptic and 
induce post-synaptic 5-HT1A gene expression to increase sero-
tonin neurotransmission in heterozygous or C/C homozygous 
subjects. However, patients with the 5-HT1A G/G(−1019) geno-
type would be expected to be resistant since the G-allele does 
not respond to Deaf1.
Since depression is twice as frequent in females compared to 
males, gender-specific alterations in 5-HT1A autoreceptor expres-
sion could mediate an increased susceptibility. In female rats and 
serotonin transporter-deficient female mice, ovariectomy results in 
increased raphe 5-HT1A receptor RNA and binding (Bouali et al., 
2003; Le Saux and Di Paolo, 2005) and increased anxiety behavior 
(Imwalle et al., 2005), while estrogen treatment reverses changes 
in 5-HT1A levels and anxiety, increasing raphe responsiveness 
(Abizaid et al., 2005). Similarly, estrogen receptor-beta knockout 
female mice display increased anxiety and reduced raphe 5-HT 
levels (Imwalle et al., 2005). In female rhesus macaques, ovariec-
tomy leads to an increase in nuclear NFkB in 5-HT raphe neu-
rons, while estrogen/progesterone reverses this (Bethea et al., 2006) 
and reduces 5-HT1A autoreceptor protein level (Henderson and 
Bethea, 2008), which could be driven by NFkB-response element 
in the 5-HT1A promoter. Thus estrogen appear to be protective 
for anxiety and negatively regulates 5-HT1A autoreceptor levels 
to enhance raphe activity, but the mechanisms of this regulation 
remain to be clarified.
Antidepressant treatments could also target cortical 5-HT1A 
receptors,  which  are  reduced  in  depression.  Down-regulation 
of Freud-1 or Freud-2 in post-synaptic regions could lead to an 
increase in 5-HT1A receptor RNA and normalize post-synaptic 
5-HT1A receptor expression and restore response of post-  synaptic 
neuron to 5-HT. Interestingly, Freud-1 RNA and protein was 
down-regulated in the prefrontal cortex of chronically stressed 
rats (Iyo et al., 2009), while 5-HT1A RNA level was increased, 
although 5-HT1A protein was reduced. Similarly in the prefrontal 
cortex of younger (<58 years) depressed subjects (especially males), 
Freud-1 RNA and protein were decreased, while 5-HT1A receptor 
protein was also reduced (Szewczyk et al., 2010). Thus, despite 
increased 5-HT1A RNA other post-translational processes, such 
as receptor down-regulation, may reduce cortical 5-HT1A protein 
levels in depression. Interestingly, cortical Freud-1 levels were not 
altered by chronic treatment of macaques with SSRI, suggesting 
that other types of antidepressant treatments may be required to 
induce this effect. Alternately, Freud-1 activity could be reduced, 
for example by calcium mobilization, which inactivates Freud-1 
(Ou et al., 2003).www.frontiersin.org    June 2010  | Volume 4  | Article 35  |  5
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